Total Payments
$12,643
2024 Payments
$2,021
Companies
33
Transactions
686
Medicare Patients
4,423
Medicare Billing
$783,033
Payment Breakdown by Category
Food & Beverage$12,127 (95.9%)
Education$496.38 (3.9%)
Travel$20.00 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,127 | 665 | 95.9% |
| Education | $496.38 | 19 | 3.9% |
| Travel and Lodging | $20.00 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $2,729 | 140 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,435 | 92 | $0 (2024) |
| ViiV Healthcare Company | $1,295 | 87 | $0 (2024) |
| Shionogi Inc | $990.58 | 32 | $0 (2024) |
| Astellas Pharma US Inc | $924.04 | 46 | $0 (2024) |
| Insmed, Inc. | $845.06 | 42 | $0 (2024) |
| Theravance Biopharma, Inc. | $700.38 | 41 | $0 (2018) |
| ABBVIE INC. | $536.82 | 30 | $0 (2024) |
| Melinta Therapeutics, LLC | $502.06 | 32 | $0 (2024) |
| La Jolla Pharmaceutical Company | $423.06 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,021 | 89 | Gilead Sciences, Inc. ($544.01) |
| 2023 | $2,592 | 118 | Gilead Sciences, Inc. ($456.91) |
| 2022 | $1,560 | 71 | Gilead Sciences, Inc. ($586.01) |
| 2021 | $1,007 | 58 | ViiV Healthcare Company ($318.94) |
| 2020 | $366.84 | 21 | ViiV Healthcare Company ($188.44) |
| 2019 | $1,597 | 103 | Gilead Sciences, Inc. ($529.15) |
| 2018 | $1,704 | 118 | Theravance Biopharma, Inc. ($262.98) |
| 2017 | $1,794 | 108 | Merck Sharp & Dohme Corporation ($487.11) |
All Payment Transactions
686 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: HIV | ||||||
| 12/19/2024 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/17/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: ANTIBIOTIC | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Infectious Diseases | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 11/26/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.80 | General |
| 11/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 11/12/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.49 | General |
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 10/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: ANTIFUNGALS | ||||||
| 10/24/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ANTIBIOTIC | ||||||
| 10/23/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Infectious Diseases | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.07 | General |
| 10/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 09/26/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: GI | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 09/17/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 975 | 98,209 | $635,702 | $150,365 |
| 2022 | 14 | 945 | 122,511 | $665,827 | $151,102 |
| 2021 | 16 | 1,090 | 60,588 | $624,984 | $196,182 |
| 2020 | 17 | 1,413 | 212,004 | $1.1M | $285,385 |
Total Patients
4,423
Total Services
493,312
Medicare Billing
$783,033
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 288 | $61,900 | $26,376 | 42.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 121 | 526 | $105,200 | $24,027 | 22.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 117 | 394 | $71,510 | $23,301 | 32.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 127 | 145 | $56,725 | $17,459 | 30.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 87 | 180 | $40,700 | $16,055 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 81 | $22,295 | $10,992 | 49.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 51 | $27,870 | $8,303 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 130 | $19,200 | $7,781 | 40.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 53 | 129 | $22,010 | $4,826 | 21.9% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 37 | 94,000 | $116,940 | $3,678 | 3.1% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 45 | 253 | $37,950 | $2,752 | 7.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,050 | $2,533 | 35.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 27 | 71 | $11,360 | $1,496 | 13.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 56 | 1,944 | $34,992 | $786.77 | 2.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 147 | 328 | $49,200 | $28,938 | 58.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 91 | 455 | $91,000 | $22,238 | 24.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 119 | 389 | $44,735 | $20,790 | 46.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 136 | 152 | $49,420 | $20,051 | 40.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 100 | 202 | $31,310 | $14,996 | 47.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 96 | $18,720 | $12,758 | 68.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 22 | 49 | $18,130 | $7,455 | 41.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 60 | 90 | $9,000 | $5,811 | 64.6% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 36 | 118,498 | $248,846 | $4,491 | 1.8% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 30 | 275 | $41,250 | $4,379 | 10.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $6,650 | $3,215 | 48.3% |
About Dr. Mark Dougherty, MD
Dr. Mark Dougherty, MD is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1326049628.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Dougherty, MD has received a total of $12,643 in payments from pharmaceutical and medical device companies, with $2,021 received in 2024. These payments were reported across 686 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($12,127).
As a Medicare-enrolled provider, Dougherty has provided services to 4,423 Medicare beneficiaries, totaling 493,312 services with total Medicare billing of $783,033. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lexington, KY
- Active Since 08/09/2005
- Last Updated 03/04/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1326049628
Products in Payments
- Fetroja (Drug) $990.58
- DOVATO (Drug) $857.79
- Arikayce (Drug) $845.06
- VIBATIV (Drug) $726.81
- DIFICID (Drug) $486.91
- AVYCAZ (Drug) $454.04
- ZERBAXA (Drug) $402.46
- Cresemba (Drug) $388.58
- XERAVA (Drug) $316.85
- NUZYRA (Drug) $307.55
- Veklury (Drug) $307.08
- Vabomere (Drug) $271.09
- Biktarvy (Drug) $237.15
- Mavyret (Drug) $229.35
- CRESEMBA (Drug) $193.97
- PIFELTRO (Drug) $171.91
- Xerava (Drug) $171.01
- VOWST (Biological) $168.38
- DALVANCE (Drug) $165.87
- ISENTRESS (Drug) $154.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Dr. David Dougherty, M.d, M.D
Infectious Disease — Payments: $110,300
Infectious Disease $110,300
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Charles Rose
Infectious Disease — Payments: $42,996
Infectious Disease $42,996
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
John Meek, Md, MD
Infectious Disease — Payments: $13,273
Infectious Disease $13,273
Dr. Andrea Banks, Md, MD
Infectious Disease — Payments: $9,877
Infectious Disease $9,877